Scientists study sugar-based H.pylori vax; Cancer vax market worth $3B in 2015;

Vaccine Research

Researchers at the University of Guelph in Canada are studying a promising sugar-based shot to combat Helicobacter pylori, a bacterium that's considered a warning sign of gastritis, ulcers and gastric cancer. Story

In an effort to eradicate bovine tuberculosis, the National Trust will begin a field trial on badgers, which may be the cause of the disease's spread. In other trials, the BCG vaccine has dropped cases of bovine TB in badgers by up to 73.8 percent. Report

Vaccine Market

According to global consulting firm Technology Catalysts International, the cancer vaccine market is poised for stellar sales in the future--up to $3 billion in 2015. The firm highlights Biovest's BiovaxID as the next cancer vax blockbuster. TCI release

The Department of Defense has awarded a Phase I Small Business Innovation Research grant to Ichor Medical Systems for its TriGrid Intradermal Delivery System (Trigrid-ID). The delivery mechanism is used to administer DNA vaccines using automated electroportation. Ichor release

Pfizer and China's Shanghai Pharmaceutical have come together to market "an innovative Pfizer product" as well as push for the use of Pfizer's Prevnar pneumococcal vaccine in China. No financial details or clarifications on the unknown Pfizer product were released. Item

The Ohio Department of Health released a report advocating the state's vaccine effort during the H1N1 flu pandemic in 2009. According to the report, more than 300,000 cases of H1N1 were prevented, including 1,400 hospitalizations and 64 deaths. Article

And Finally... Vaccine supporters, including the American Academy of Pediatrics, are pushing for the removal of an anti-vaccine advertisement in New York City's Times Square, which will remain up for 15 seconds every hour through April 28. The ad, which is broadcast on a CBS Outdoor billboard, is paid for by the National Vaccine Information Center and Mercola.com. Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.